BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Veristat expands operations into Taiwan

August 1, 2019 | News

To support growing client demand for clinical trial, biostatistics and programming excellence in the region



US headquartered Veristat, a scientifically oriented clinical development, and regulatory submission partner, announces the formal launch of its Clinical Trial, Biostatistics and Programming operations in Taipei, Taiwan with the opening of a new office.

“The growth of Veristat’s operations in Taiwan is a critical next step in supporting our clients looking to prepare their clinical trial data for marketing applications worldwide,” stated Patrick Flanagan, Chief Executive Officer at Veristat. “We have strategically selected Taipei, Taiwan, as our entry into Asia because the location complements our core values and culture of partnership, respect, innovation, and agility. We are building a highly-experienced team of statistical programmers and clinical trial professionals in our new Taipei office to better serve our clients and their increasing requests for local and international regulatory submission support.”

Leading the Veristat operations in this fast-growing region is Shengfeng (Philip) Ho, MS. Mr. Ho joined Veristat as the Director of Taipei Operations and Manager of Statistical Programming in October 2018. He is a database and statistical programming expert with over ten years of experience working with and growing Statistical Programming teams for life science companies and clinical research organizations (CROs) in China. Additionally, Mr. Ho has served as a CDISC fellow for the past five years, where he developed dataset examples for published therapeutic area standards for CDISC Shared Health and Research Electronic Library (SHARE) metadata repository. Mr. Ho received his Master of Science (MS) degree in Applied Statistics at Fu Jen Catholic University, Taiwan in 2004 and his Bachelor of Science (BS) degree in Mathematical Statistics at TamKang University, Taiwan in 2002.